Renin-Angiotensin-Aldosterone System Inhibitors and the Risk of AKI in COVID-19 Compared with Influenza

Birkelo, Bethany C.; Parr, Sharidan K.; Perkins, Amy M.; Greevy, Robert A.; Arroyo, Juan Pablo; Hung, Adriana M.; Vincz, Andrew J.; Shah, Shailja C.; Kapoor, Tarun M.; Matheny, Michael E.; Siew, Edward D.

doi:10.2215/cjn.11190821

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of IgA Glomerulonephritis, AKI can occur when IgA deposits lead to a loss of kidney filtering ability ( Wei et al, 2021 ; Li et al, 2023 ). Additionally, AKI exacerbations are often triggered by viral infections, including influenza ( Mohammad et al, 2021 ; Birkelo et al, 2022 ). The co-infection risk between influenza A virus and SARS-CoV-2 is a significant concern for public health officials and clinicians ( Solomon et al, 2020 ; Mehta et al, 2021 ; Qian et al, 2023b ; Sun et al, 2023 ).…”

Section: Discussionmentioning

confidence: 99%

Deciphering the molecular nexus between Omicron infection and acute kidney injury: a bioinformatics approach

Wang,

Chen,

Zhang

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

BackgroundThe ongoing global health crisis of COVID-19, and particularly the challenges posed by recurrent infections of the Omicron variant, have significantly strained healthcare systems worldwide. There is a growing body of evidence indicating an increased susceptibility to Omicron infection in patients suffering from Acute Kidney Injury (AKI). However, the intricate molecular interplay between AKI and Omicron variant of COVID-19 remains largely enigmatic.MethodsThis study employed a comprehensive analysis of human RNA sequencing (RNA-seq) and microarray datasets to identify differentially expressed genes (DEGs) associated with Omicron infection in the context of AKI. We engaged in functional enrichment assessments, an examination of Protein-Protein Interaction (PPI) networks, and advanced network analysis to elucidate the cellular signaling pathways involved, identify critical hub genes, and determine the relevant controlling transcription factors and microRNAs. Additionally, we explored protein-drug interactions to highlight potential pharmacological interventions.ResultsOur investigation revealed significant DEGs and cellular signaling pathways implicated in both Omicron infection and AKI. We identified pivotal hub genes, including EIF2AK2, PLSCR1, GBP1, TNFSF10, C1QB, and BST2, and their associated regulatory transcription factors and microRNAs. Notably, in the murine AKI model, there was a marked reduction in EIF2AK2 expression, in contrast to significant elevations in PLSCR1, C1QB, and BST2. EIF2AK2 exhibited an inverse relationship with the primary AKI mediator, Kim-1, whereas PLSCR1 and C1QB demonstrated strong positive correlations with it. Moreover, we identified potential therapeutic agents such as Suloctidil, Apocarotenal, 3′-Azido-3′-deoxythymidine, among others. Our findings also highlighted a correlation between the identified hub genes and diseases like myocardial ischemia, schizophrenia, and liver cirrhosis. To further validate the credibility of our data, we employed an independent validation dataset to verify the hub genes. Notably, the expression patterns of PLSCR1, GBP1, BST2, and C1QB were consistent with our research findings, reaffirming the reliability of our results.ConclusionOur bioinformatics analysis has provided initial insights into the shared genetic landscape between Omicron COVID-19 infections and AKI, identifying potential therapeutic targets and drugs. This preliminary investigation lays the foundation for further research, with the hope of contributing to the development of innovative treatment strategies for these complex medical conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Deciphering the molecular nexus between Omicron infection and acute kidney injury: a bioinformatics approach

Wang,

Chen,

Zhang

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Since AKI patients could have an increased likelihood of being ventilated or prescribed vasopressors, caution should be exercised when interpreting these risk factors. Some additional risk factors for AKI and AKI severity, such as apolipoprotein L1 genetic variation and use of renin-angiotensin-aldosterone system inhibitors ( 59 , 60 ), have been suggested by recent studies but have not yet been assessed on a meta-analysis level.…”

Section: Discussionmentioning

confidence: 99%

Kidney health in the COVID-19 pandemic: An umbrella review of meta-analyses and systematic reviews

Yang

Wei

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThis umbrella review aims to consolidate evidence from systematic reviews and meta-analyses investigating the impact of the coronavirus disease−2019 (COVID-19) on kidney health, and the associations between kidney diseases and clinical outcomes in COVID-19 patients.MethodsFive databases, namely, EMBASE, PubMed, Web of Science, the Cochrane Database of Systematic Reviews and Ovid Medline, were searched for meta-analyses and systematic reviews from January 1, 2020 to June 2, 2022. Two reviewers independently selected reviews, identified reviews for inclusion and extracted data. Disagreements were resolved by group discussions. Two reviewers independently assessed the methodological quality of all included reviews using ROBIS tool. A narrative synthesis was conducted. The characteristics and major findings of the included reviews are presented using tables and forest plots. The included meta-analyses were updated when necessary. The review protocol was prospectively registered in PROSPERO (CRD42021266300).ResultsA total of 103 reviews were identified. Using ROBIS, 30 reviews were rated as low risk of bias. Data from these 30 reviews were included in the narrative synthesis. Ten meta-analyses were updated by incorporating 119 newly available cohort studies. Hospitalized COVID-19 patients had a notable acute kidney injury (AKI) incidence of 27.17%. AKI was significantly associated with mortality (pooled OR: 5.24) and severe conditions in COVID-19 patients (OR: 14.94). The pooled prevalence of CKD in COVID-19 patients was 5.7%. Pre-existing CKD was associated with a higher risk of death (pooled OR: 2.21) and disease severity (pooled OR: 1.87). Kidney transplant recipients were susceptible to SARS-CoV-2 infection (incidence: 23 per 10,000 person-weeks) with a pooled mortality of 18%.ConclusionKidney disease such as CKD or recipients of kidney transplants were at increased risk of contracting COVID-19. Persons with COVID-19 also had a notable AKI incidence. AKI, the need for RRT, pre-existing CKD and a history of kidney transplantation are associated with adverse outcomes in COVID-19.Systematic review registrationwww.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021266300, identifier: CRD42021266300.

show abstract

Renin-Angiotensin-Aldosterone System Inhibitors and the Risk of AKI in COVID-19 Compared with Influenza

Cited by 2 publications

References 5 publications

Deciphering the molecular nexus between Omicron infection and acute kidney injury: a bioinformatics approach

Deciphering the molecular nexus between Omicron infection and acute kidney injury: a bioinformatics approach

Kidney health in the COVID-19 pandemic: An umbrella review of meta-analyses and systematic reviews

Contact Info

Product

Resources

About